(AGENPARL) - Roma, 18 Dicembre 2025 - (AGENPARL) – Thu 18 December 2025 No images? Click here https://hq_who_departmentofcommunications.cmail20.com/t/d-e-gtuhilk-iitylyihjr-u/
Thursday, 18 December 2025
Note to media
Updated COVID-19 vaccine composition recommendation
The World Health Organization (WHO) Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has issued updated recommendations. The objective of the updated vaccine composition is to enhance immune responses against circulating variants and provide broader protection, as SARS-CoV-2, the virus that causes COVID-19, continues to evolve.
TAG-CO-VAC advises manufacturers that monovalent LP.8.1 is the recommended antigen for COVID-19 vaccines. Previously recommended antigens from the JN.1 lineage (JN.1 or KP.2) remain suitable alternatives. Vaccination remains important and should not be delayed while awaiting LP.8.1-based vaccines.
TAG-CO-VAC is an independent group of experts that advises WHO on vaccine composition. They convened in December 2025 for their twice-yearly meeting to review the evolution of SARS-CoV-2 variants; immune responses to SARS-CoV-2 infection and COVID-19 vaccination; and the performance of vaccine products against circulating variants.
Read the technical statement [https://www.who.int/news/item/18-12-2025-statement-on-the-antigen-composition-of-covid-19-vaccines].
Related links
About the [https://www.who.int/groups/technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)] Technical Advisory Group on COVID-19 Vaccine Composition [https://www.who.int/groups/technical-advisory-group-on-covid-19-vaccine-composition-(tag-co-vac)] COVID-19 data dashboard [https://data.who.int/dashboards/covid19/summary?n=o] COVID-19 fact sheet [https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19)]
Media contacts: